Follows pregnant people with migraine who take rimegepant
Tracks outcomes for mothers, fetuses and infants after rimegepant exposure.
Plain-language title generated from the registry record
Registry title: Observational Study to Assess Maternal, Fetal and Infant Outcomes Following Exposure to Rimegepant
Key facts
- Where
- Wilmington, United StatesSee the site
Where in United States
- Evidera, a PPD business unitWilmington, United StatesTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Pfizer
- Trial code
- NCT05046613
- Record updated
- 29 October 2026
- Original description
The purpose of the study is to evaluate fetal, maternal, and infant outcomes through 12 months of age.Read full original descriptionShow less
A Prospective, Registry-based, Observational Study to Assess Maternal, Fetal and Infant Outcomes Following Exposure to Rimegepant: The Migraine Observational Nurtec Pregnancy Registry (MONITOR)
The purpose of the study is to evaluate fetal, maternal, and infant outcomes through 12 months of age.
Inclusion: Pregnant women with migraine exposed to rimegepant: a diagnosis of migraine and at least 1 dose of rimegepant during pregnancy or just prior to pregnancy (up to 3 days prior to conception); Pregnant women with migraine unexposed to rimegepant: a diagnosis of migraine and no exposure to Rimegepant before or during pregnancy.
Exclusion: Women exposed to other calcitonin gene-related peptide (CGRP)antagonists (e.g., ubrogepant), CGRP monoclonal antibodies, or ditans (e.g., lasmiditan) at any time during pregnancy or just prior to pregnancy.